Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-IMH
NL-OMON59196Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in acute ST-segment elevation myocardial infarction (STEMI) comparing Ticagrelor monotherapy after primary PCI with Ticagrelor plus aspirin for 12 months (2 arms). Primary endpoints: Major adverse cardiac and cerebral events, Infarct size by cardiac MRI and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NL-OMON59196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59196.